Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | LOX | P28300 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10428547 | 0.93 | CSNK2A1 (0.45) | KDM4EATMCA2CYP19A1ALDH1A1 | |
| SCHEMBL19409880 | 0.85 | ATM (0.70) | KDM4EATMCA2CYP19A1AOC3 | |
| SCHEMBL29535675 | 0.85 | ATM (0.70) | KDM4EATMCA2CYP19A1AOC3 | |
| SCHEMBL44393 | 0.85 | ATM (0.70) | KDM4EATMCA2CYP19A1AOC3 | |
| SCHEMBL6943325 | 0.84 | KDM4E (0.51) | KDM4EATMCA2CYP19A1ALDH1A1 | |
| SCHEMBL5708146 | 0.84 | CALM1 (0.61) | KDM4EATMCA2CYP19A1CALM1 | |
| Hydrochloric Acid SCHEMBL9726669 | 0.83 | ATM (0.68) | KDM4EATMCA2CYP19A1AOC3 | |
| SCHEMBL8107846 | 0.82 | KDM4E (0.58) | KDM4EATMCA2CSNK2A1 | |
| Hydrochloric Acid SCHEMBL5708154 | 0.82 | KDM4E (0.64) | KDM4EATMCA2CYP19A1CALM1 | |
| SCHEMBL6301878 | 0.82 | POLB (0.56) | KDM4EATMCA2CALM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569505-B2 | Aminotetralin-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, NV (BE) | 2013-10-29 | — | — | US | disclosed |
| EP-1506166-B1 | AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-16 | — | — | EP | disclosed |
| WO-2011131712-A1 | METAL HYBRID COMPOSITE CASTING | Rheinisch-Westfälische Technische Hochschule Aachen (DE) | 2011-10-27 | — | — | WO | disclosed |
| US-20100125140-A1 | AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR | CODD ELLEN | 2010-05-20 | — | — | US | disclosed |
| US-7678812-B2 | Aminotetralin-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2010-03-16 | — | — | US | disclosed |
| US-20080097102-A1 | AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR | CODD ELLEN | 2008-04-24 | — | — | US | disclosed |
| US-6984647-B2 | Aminotetralin-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-10 | — | — | US | disclosed |
| US-20050187291-A1 | use of 2-(urea or thiourea)tetralins as analgesic or to treat pulmonary dysfunction | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-25 | — | — | US | disclosed |
| EP-1506166-A1 | AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | disclosed |
| US-20030236280-A1 | Aminotetralin-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-12-25 | — | — | US | disclosed |
| WO-2003097586-A1 | AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125140-A1 | AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR | UTS2R, TRPV1, GPR17 | KDM4E 3753/4885ATM 3990/4885CA2 2811/4885 |
| US-20080097102-A1 | AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR | UTS2R, TRPV1, GPR17 | KDM4E 3753/4885ATM 3990/4885CA2 2811/4885 |
| US-20050187291-A1 | use of 2-(urea or thiourea)tetralins as analgesic or to treat pulmonary dysfunction | TMEM109, UTS2R, GPR17 | KDM4E 4659/4885ATM 4045/4885CA2 969/4885 |
| US-20030236280-A1 | Aminotetralin-derived urea modulators of vanilloid VR1 receptor | UTS2R, TRPV6, TRPV1 | KDM4E 3638/4885ATM 3895/4885CA2 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.